NEXGEL, Inc. NXGL NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score

45/100

2/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

NEXGEL, Inc. (NXGL) has a negative trailing P/E of -1.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -62.62%, forward earnings yield 38.61%. PEG 0.12 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -1.6); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -62.62%).
Forward P/E 2.6 — analysts expect a return to profitability with estimated EPS of $0.23 for FY2027.
PEG Ratio 0.12 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Trailing Earnings Yield -62.62% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 38.61% as earnings recover.

Overall SharesGrow Score: 44/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

45/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✗

HEALTH

33/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

36/100

→ Income

✓

GROWTH

90/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — NXGL

Valuation Multiples

P/E (TTM)-1.6

Forward P/E2.6

PEG Ratio0.12

Forward PEG0.12

P/B Ratio1.07

P/S Ratio0.57

EV/EBITDA-4.4

Per Share Data

EPS (TTM)$-0.38

Forward EPS (Est.)$0.23

Book Value / Share$0.62

Revenue / Share$1.45

FCF / Share$-0.17

Yields & Fair Value

Earnings Yield-62.62%

Forward Earnings Yield38.61%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-11.0	0.00	24.67	9.10	-
2017	-20.6	0.44	31.34	9.83	-
2018	-10.4	-0.10	69.71	8.85	-
2019	-10.2	-3.46	51.55	27.32	-
2020	-8.7	-0.50	275.90	29.06	-
2021	-3.4	-0.04	1.20	9.38	-
2022	-1.5	-0.14	0.91	3.40	-
2023	-3.8	0.11	2.57	2.95	-
2024	-8.9	0.83	5.05	3.34	-
2025	-4.2	0.18	2.84	1.11	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-0.32	$2.15M	$-1.78M	-82.5%
2017	$-0.17	$1.99M	$-953K	-47.8%
2018	$-0.34	$2.21M	$-1.89M	-85.3%
2019	$-0.14	$717K	$-1.92M	-268.2%
2020	$-0.02	$674K	$-2.28M	-338.6%
2021	$-1.13	$1.55M	$-6.31M	-406.7%
2022	$-1.10	$2.05M	$-6.14M	-300%
2023	$-0.56	$4.09M	$-3.16M	-77.2%
2024	$-0.50	$8.69M	$-3.28M	-37.8%
2025	$-0.38	$11.42M	$-3M	-26.3%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.06	$-0.06 – $-0.06	$16.88M	$16.88M – $16.88M	1
2027	$0.23	$0.23 – $0.23	$24.67M	$24.67M – $24.67M	1
2028	$0.19	$0.19 – $0.19	$32.34M	$32.34M – $32.34M	1
2029	$0.30	$0.30 – $0.30	$41.29M	$41.29M – $41.29M	1
2030	$0.41	$0.41 – $0.41	$52.39M	$52.39M – $52.39M	1